Across TCGA pan-cancer cohorts, PDZD3 mass-spec protein differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of PDZD3’s most consistent transcriptional readouts.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where PDZD3 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types PDZD3 is over-expressed in tumor, although a few such as CCRCC show the opposite, repressed pattern.
CCRCC are the cancer types where PDZD3 tumor–normal differential expression is most reproducible.